UnknownPhase 3

17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor

Israel800 participantsStarted 2010-12

Plain-language summary

Preterm deliveries play a significant role in neonatal morbidity and mortality. Previous studies showed that administration of progesterone to pregnant women at high risk, decrease spontaneous preterm deliveries. The purpose of this study is to compare between two different modes of treatment with progesterone for the prevention of preterm delivery: weekly injection of 17 alfa hydroxyprogesterone caproate versus daily vaginal administration of progesterone in terms of efficacy, comfort and compliance, safety and cost of treatments.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The subject has a history of spontaneous preterm delivery defined as earlier than 37 gestational week. * The subject has a short cervical length defined as 25 mm before 24 weeks gestation. * A singleton gestation. Exclusion Criteria: * Multifetal pregnancy. * The subject has or will have a cervical cerclage in place.

What they're measuring

efficacy

Timeframe: 3 years

Trial details

NCT IDNCT00809939

SponsorMeir Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Pregnancy trials